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Structured abstract
Background: Recent reports have provided evidence that bridging therapy with low-molecularweight heparin (LMWH) may increase bleeding complications in patients with atrial fibrillation (AF) on oral anticoagulation undergoing percutaneous coronary intervention (PCI). We sought to assess mid-term bleeding and thromboembolic events in patients from the AFCAS registry discharged on triple therapy (TT).
Methods: AFCAS is a multicenter, prospective registry enrolling patients with AF undergoing PCI.
The primary endpoints were: 1) bleeding complications as defined by the bleeding academic research criteria (BARC); 2) a composite of cardiac and cerebrovascular events (MACCE) at 3 and 12 months follow-up.
Results: Altogether 663 out of 929 consecutive patients were discharged on TT, either on oral vitamin K antagonist (VKA-TT) (n=498) or bridging LMWH-TT (n=165). Patients on LMWH-TT had more often diabetes, heart failure, and hypertension compared to those on VKA-TT. The rates of major bleeding events (BARC ≥3) (11.5% vs. 6.0%, p=0.03) as well as MACCE (11.5% vs. 5.0%, p=0.006) were higher in the LMWH-TT group compared to VKA-TT group at 3 months follow-up.
In a Cox multivariate regression model and propensity-score matched analysis LMWH-TT increased the risk for major BARC bleeding events at 3 and 12 months follow-ups.
Conclusions: In this large, prospective, real-world population of patients with AF undergoing PCI patients discharged on LMWH-TT had a significantly higher risk for major bleeds in comparison to patients discharged on VKA-TT. LMWH-bridging therapy appeared harmful in this subset of patient on oral anticoagulation.
Introduction
In accordance with current guidelines, the antithrombotic therapy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent implantation (PCI) should consist of triple therapy (TT) of vitamin K-antagonist (VKA), aspirin, and clopidogrel when the thromboembolic risk is moderate to high (CHA 2 DS 2 VASC score ≥2) 1 . TT is the treatment of choice at least in the first month after stent implantation 1, 2 . Data on patients after PCI who have an indication for VKA are limited 3, 4 . Previously bridging treatment with low-molecularweight heparin (LMWH) has been the standard recommendation for patients if VKA has to be interrupted or introduced 5, 6 . However, recent expert recommendations suggest that in patients on oral anticoagulation with CHA2DS2-VASc ≥2 and stable angina, an uninterrupted anticoagulation strategy with no additional heparin boluses during PCI is the preferred strategy (Class IIa, level of evidence C) 1 . Little is known about the outcomes of LMWH-bridging therapy in long-term follow-up as well as in patients presenting with acute coronary syndrome.
In this pre-specified analysis, we prospectively assessed the effect of LMWH-bridging therapy vs. uninterrupted oral anticoagulation therapy on thrombotic and bleeding events in patients with AF undergoing stent implantation with an indication for TT.
Methods
Study population
AFCAS is an observational, multicenter, prospective registry including patients with AF who are referred for PCI (Clinicaltrials.gov identifier NCT00596570). Inclusion criteria were elective or urgent/emergency PCI and 1) history of AF (paroxysmal, persistent, or permanent), or 2) AF during the index hospital stay. Because of the observational design, the only exclusion criterion was unwillingness/inability to participate in the study or to give written informed consent. Coronary angiography and PCI were performed using either radial or femoral approach for arterial access and haemostasis was obtained according to the local practice. Lesions were treated according to contemporary interventional techniques.
LMWH (enoxaparin sodium, dalteparin), unfractionated heparin, bivalirudin and glycoprotein IIb/IIIa inhibitors were administered entirely at the operator's discretion.
Moreover, the choice of the combination of antithrombotic treatment after the procedure was at the treating physician's discretion.
Details of the study have been published elsewhere [7] [8] [9] [10] . At each participating center, patients were treated according to local policies, and were followed up for 12 months (phone call at 3, 6 and 12 months and when needed by assessment of patient records in the hospitals and in health centers of catchment areas. Each event was adjudicated according to the prespecified definitions for myocardial infarction, target vessel revascularization, stent thrombosis transient ischemic attack and stroke [7] [8] [9] [10] . Bleeding events were centrally adjudicated based on the patient record data on case report forms. The study complied with the Declaration of
Helsinki. Ethic committees of participating centers approved the study protocol, and written informed consent was obtained from every patient.
This analysis included patients discharged on TT including VKA, aspirin and clopidogrel (VKA-TT) and those on LMWH-bridging therapy, aspirin and clopidogrel (LMWH-TT). 
Study endpoints
Results
Out of 663 patients discharged on TT, 498 (75.1%) were on VKA-TT and remaining 165 (24.9%) on LMWH-TT. Baseline and procedural characteristics according to VKA-TT vs. LMWH-TT are presented in Tables 1 and 2 
Adverse events at 3 months as well as 12 months follow-up are presented in Table 3 . The rate of major bleeding events (BARC ≥3) was significantly higher in the LMWH-TT group compared to VKA-TT group at 3 months follow-up. The rate of MACCE was also significantly higher in the LMWH-TT group compared to VKA-TT group. Figure 1 presents the freedom from major bleeding at 3 months follow-up and Figure 2 freedom from MACCE at 12 months followup. Patients on LMWH-TT group had more major bleeding events early within 30 days after the index procedure compared to those on VKA-TT. A significant difference in the occurrence of MACCE was also observed throughout the entire follow-up.
Since the study groups differed significantly in certain baseline characteristics as shown
in Tables 1 and Table 2 
Discussion
Bridging therapy with LMWH in addition to dual antiplatelet therapy appeared to increase the rate of major bleeding events compared to uninterrupted oral VKA-TT in this "real world" registry of patients with AF undergoing PCI. Moreover, LMWH-TT was associated with increased rate of thrombotic/thromboembolic events and prolonged hospital stay, and a 3-fold increase of bleeding events in the propensity score matched model.
Anticoagulation therapy is recommended in patients with AF and a moderate to high risk for strokes as defined by a CHA 2 DS 2 -VASC-score ≥2 to avoid stroke and other thromboembolic events 1 . In patients undergoing PCI with stent implantation, clinical decision-making is challenging since the combination of aspirin and a P2Y 12 -inhibitor is also indicated to prevent stent thrombosis. TT should always be considered to carry an increased risk of overall bleeding and should therefore be reserved for those patients for whom the expected net clinical benefit is favorable. Consequently, guidelines recommend in patients with an indication for oral
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9 anticoagulation after PCI the combination of VKA, aspirin and clopidogrel (VKA-TT) for at least one month, although risk for severe bleedings increases substantially under VKA-TT 1 . In addition, VKA plus clopidogrel treatment may be considered in patients at low bleeding risk 1, 13 .
Recent randomized trials showed that uninterrupted oral anticoagulation therapy was associated with substantially decreased 0.19-fold risk in the rate of major bleeding events after pacing-device implantation 14 and 0.08-fold risk in the catheter ablation of AF compared to bridging therapy 15 . There are, however, no randomized trials assessing the safety or risks of bridging therapy during PCI. In the earlier non-randomized studies, the strategy of uninterrupted oral anticoagulation has been at least as safe as warfarin pause combined with heparin bridging, but the low methodological quality of studies precludes any definitive conclusions 4, 16 . The present analysis gives important additional information on this topic. It is the first to focus on patients with an indication for TT and also assess the 1-year outcome of the patients using also propensity score-matching to adjust for differences in the patient groups.
Our study supports the view that uninterrupted oral anticoagulation strategy should be Finally, the question of whether uninterrupted oral anticoagulation is associated with a higher risk of bleeding because of difficulties in controlling haemorrhage appears not valid, because rapid reversal of anticoagulation can be obtained using plasma and/or coagulation proteins. Of note, reversal of the anticoagulant effect of enoxaparin and fondaparinux, which are the recommended anticoagulants in acute coronary syndromes, may be more cumbersome, since protamine sulphate (the established antidote to unfractionated heparin) has little or no effect in neutralizing these agents.
Limitations
Significant baseline differences between the study groups were accounted using multivariate Cox regression modeling and propensity score matched pairs. The large differences between the study populations led to a propensity score with a rather large under the ROC curve. This in turn led to a reduced, but very tightly matched pairs. The difference between the results of multivariate analysis and propensity-adjusted analysis could be due to a reduced number of patients available for propensity score calculation as well as the fact that propensity score has dealt with a much larger number of variables. Nevertheless, major bleeding events were more frequent with all these methods.
Conclusion
In this large, prospective, real-world population of patients with AF undergoing PCI patients discharged on LMWH-TT had a significantly higher risk for major bleeds in comparison to patients discharged on VKA-TT. LMWH-bridging therapy appeared harmful in this subset of patient on oral anticoagulation.
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